A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.

  title={A novel histone deacetylase (HDAC) inhibitor MHY219 induces apoptosis via up-regulation of androgen receptor expression in human prostate cancer cells.},
  author={Nabanita Patra and Umasankar De and Tae Hyung Kim and Young Ju Lee and Mee Young Ahn and Nam Deuk Kim and Jung Hyun Yoon and Wahn Soo Choi and Hyung Ryong Moon and Byung Mu Lee and Hyung Sik Kim},
  journal={Biomedicine \& pharmacotherapy = Biomedecine \& pharmacotherapie},
  volume={67 5},

Figures from this paper

A New Histone Deacetylase Inhibitor, MHY219, Inhibits the Migration of Human Prostate Cancer Cells via HDAC1

The results suggest that MHY219 may potentially be used as an anticancer agent to block cancer cell migration through the repression of MMP-1 and M MP-2, which is related to the reduction of HDAC1.

Anticancer Effects of a New SIRT Inhibitor, MHY2256, against Human Breast Cancer MCF-7 Cells via Regulation of MDM2-p53 Binding

Results suggest that a new SIRT inhibitor, MHY2256, has anticancer activity through p53 acetylation in MCF-7 human breast cancer cells.

Cytostatic Action of Novel Histone Deacetylase Inhibitors in Androgen Receptor-Null Prostate Cancer Cells

Results showed that Jazz90 and Jazz167 function as cytostatic HDAC inhibitors in AR-null prostate cancer cells, and showed that apoptosis only occurred at a maximum of 7% of the total cell population following compound treatments in PC3 and DU145 cells.

Design of Fluorescent Coumarin-Hydroxamic Acid Derivatives as Inhibitors of HDACs: Synthesis, Anti-Proliferative Evaluation and Docking Studies

It is concluded that compounds 7c, 7e, 7f, 7i and 7j may be considered as potential anticancer agents, considering their antiproliferative properties, their effect on the regulation of the genes, as well as their capacity to dock to the active sites.

Pro-apoptotic effect of the novel benzylidene derivative MHY695 in human colon cancer cells

MHY695 exhibited potent anti-cancer effects in four different types of human colon cancer cell line, including Caco-2, DLD-1, HT-29 and HCT116, and showed reduced cytotoxicity in NCM460, normal colonic epithelial cells.

Histone deacetylase inhibition disturbs the balance between ACE and chymase expression in endothelial cells: a potential mechanism of chymase activation in preeclampsia

It is concluded that aberrant HDAC expression/activity could disturb the balance between ACE and chymase expression in endothelial cells and support the clinical importance of chymases as a new pharmacological target for cardiovascular disorders.

Analysis of miRNAs related to abnormal HDAC 1 expression in hepatocellular carcinoma

The results suggest that microRNA is able to regulate HDAC1 expression, exerting anti-tumor effects, which provides a new clue for the diagnosis and treatment of HCC.

Histone deacetylase inhibition activates Nrf2 and protects against osteoarthritis

Nrf2 has a major chondroprotective role in progression of OA and is a critical molecule in HDACi-mediated OA protection.

Distinct Phenotypes of Human Prostate Cancer Cells Associate with Different Adaptation to Hypoxia and Pro-Inflammatory Gene Expression

The data highlight that tumor prostate cell phenotype contributes at a different degree and with different mechanisms to the hypoxic pro-inflammatory gene expression related to tumor progression.

Exploring novel capping framework: high substituent pyridine-hydroxamic acid derivatives as potential antiproliferative agents

High substituted pyridine showed cell growth inhibition, regulation of genes related to cell cycle progression in highly metastatic cancer cell lines, and the highest antiproliferative activity in the breast and prostate cancers cell lines at a concentration of 10 µM.



Anti-tumor effect of apicidin on Ishikawa human endometrial cancer cells both in vitro and in vivo by blocking histone deacetylase 3 and 4.

It is suggested that apicidin is an effective anti-tumor agent on human endometrial cancer cells, and acts by regulating cell proliferation and apoptosis through the down-regulation of HDAC3 and HDAC4.

Histone deacetylase inhibitors: mechanism of action and therapeutic use in cancer

Histone deacetylases (HDACs) remove the acetyl groups of lysine residues of histone tails leading to chromatin compaction and transcriptional repression. In addition, HDACs can also influence

Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy

It is shown that the known effects of HDACs on differentiation and proliferation of cancer cells observed in vitro can also be confirmed in vivo.

Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review).

Based on the ability of HDACIs to regulate many signaling pathways, co-treatment of these compounds with molecular targeted drugs is a promising strategy against many types of tumors.

Histone acetylation may suppress human glioma cell proliferation when p21 WAF/Cip1 and gelsolin are induced.

Results from in vitro studies indicate that the treatment of human glioma cells with one of the histone deacetylase inhibitors suppresses cell growth with decreasing DNA synthesis and stimulates apoptosis, and that associated molecular mechanisms responsible for these effects include increased histone acetylation as well as enhanced expression of p21 and gelsolin.

Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.

The results suggest that hydroxamic acid-based hybrid polar compounds inhibit prostate cancer cell growth and may be useful, relatively nontoxic agents for the treatment of prostate carcinoma.

HDAC4 promotes growth of colon cancer cells via repression of p21.

It is demonstrated that HDAC4 is expressed in the proliferative zone in small intestine and colon and that its expression is down-regulated during intestinal differentiation in vivo and in vitro.

Histone deacetylase and DNA methyltransferase in human prostate cancer.

This is the first report to demonstrate that DNMT1 and HDAC1 levels are up-regulated in prostate cancer compared to BPH, suggesting their roles in inactivation of various genes, by DNA-methylation-induced chromatin-remodeling, in prostatecancer.